Prana candidate reduces Abeta levels

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.

The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.

PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.

The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd